nick DNA and induce mutations with potentially high efficiencies by an unknown mechanism 4, 10, 11, 13 , thereby creating the risk of unwanted off-target mutations. The extent of these off-target alterations caused by the activities of single nickases remains unclear because no unbiased, genome-wide method for assessing off-target effects yet exists. Thus, to our knowledge, a truly dimeric Cas9-based system with improved specificities has yet to be described.
nick DNA and induce mutations with potentially high efficiencies by an unknown mechanism 4, 10, 11, 13 , thereby creating the risk of unwanted off-target mutations. The extent of these off-target alterations caused by the activities of single nickases remains unclear because no unbiased, genome-wide method for assessing off-target effects yet exists. Thus, to our knowledge, a truly dimeric Cas9-based system with improved specificities has yet to be described.
Here we describe RFNs for which dimerization, rather than just colocalization, is required for efficient genome editing activity. These new nucleases can robustly induce genome editing events with high frequencies in human cells and can reduce known off-target mutations to undetectable levels as judged by sensitive, deep-sequencing methods. We also developed a system for expressing pairs of gRNAs bearing any 5' end nucleotide, a method that confers a useful targeting range on this platform. Finally, we show that monomeric Cas9 nickases generally introduce more undesirable indels and point mutations (to our knowledge, a previously unknown side effect) than RFNs in the presence of a single gRNA. Our results define a robust, user-friendly, nextgeneration CRISPR-based platform with the specificity advantages of a well-characterized dimeric architecture and an improved mutagenesis profile relative to paired Cas9 nickases, features that will be beneficial for research and therapeutic applications requiring the highest possible genome editing precision.
RESULTS

Strategy for designing dimeric RNA-guided nucleases
To develop RNA-guided nucleases with increased specificity, we fused the well-characterized, dimerization-dependent, wild-type FokI Zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered, regularly interspaced, short palindromic repeat (CRISPR)-CRISPR-associated (Cas) nucleases are broadly useful technologies for targeted genome editing [1] [2] [3] . Repair of nuclease-induced double-stranded breaks by nonhomologous end-joining (NHEJ) or homology-directed repair can stimulate efficient introduction of variable-length insertion/deletion mutations (indels) or specific sequence alterations, respectively. Dimeric ZFNs and TALENs recognize extended sequences consisting of two "half-sites, " each bound by one monomer, and cleave intervening spacer sequences using their dimerization-dependent FokI nuclease domains 2, 3 . By contrast, the monomeric Streptococcus pyogenes Cas9 nuclease (hereafter referred to as Cas9) can be directed to cleave specific DNA sequences by an associated ~100-nt single guide RNA (gRNA) 4 ,5 bearing 17-20 nt of target site complementarity at its 5ʹ end. DNA sites to be cleaved by Cas9 must also lie next to a protospacer adjacent motif (PAM) sequence of the form 5ʹ-NGG 6 .
The simplicity of the Cas9 system has made it an increasingly popular tool for research, but an important concern with these monomeric nucleases, particularly for human therapeutic applications, has been the frequency and magnitude of unwanted off-target indel mutations [7] [8] [9] . Dimerization is an attractive strategy for improving the specificity of Cas9 nucleases. Although recent work has described a paired Cas9 nickase approach for improving specificity [10] [11] [12] , this system is not truly dimerization-dependent. Rather, paired nickases require only colocalization of two Cas9 nickases on a segment of DNA, which then induces high efficiency genome editing by means of an undefined mechanism [10] [11] [12] . As dimerization of Cas9 nickases is not a requirement for enzymatic activity, each single Cas9 nickase in a pair can independently Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing a U6 promoter in most expression vectors. If the 5ʹG requirement could be relieved, then the targeting range would be improved by 16-fold.
To develop a system that permits multiplex expression of gRNAs bearing any 5ʹ nucleotide, we designed a plasmid from which two or more gRNAs, each flanked by cleavage sites for the Csy4 RNase of Pseudomonas aeruginosa 15 , could be expressed within a single RNA transcribed from a single U6 promoter (Fig. 1b) . Similarly to what occurs when endogenous Csy4 processes CRISPR-derived RNAs in bacteria 15 , co-expressed Csy4 would be expected to cleave this transcript, thereby releasing the gRNAs. Based on the known mechanism of Csy4-mediated cleavage 15, 16 , each processed gRNA should retain a Csy4 recognition site on its 3ʹ end with a Csy4 protein bound to that site (Fig. 1b) . Because gRNAs are precisely cleaved out from the larger transcript, this system should, in principle, permit the expression of gRNAs bearing any 5ʹ nucleotide.
We initially tested whether gRNAs expressed in such a Csy4-based system would be as active in human cells as those expressed from a standard U6 promoter plasmid. To do this, we directly compared the abilities of single gRNAs expressed in each system to direct Cas9-mediated nuclease domain to a catalytically inactive Cas9 (dCas9) protein. We imagined that, like FokI-based ZFNs and TALENs, dimers of our fusions might mediate sequence-specific DNA cleavage when bound to target sites composed of two "half-sites" (each bound by one dCas9 monomer domain) with a certain length 'spacer' sequence between them (Fig. 1a) . We hypothesized that these fusions would have enhanced specificity compared to the standard monomeric Cas9 nucleases and the paired nickase system because they should require two gRNAs for activity (Fig. 1a) , and because a single gRNA would presumably be unable to recruit the two FokI-containing fusion proteins required for DNA cleavage.
Multiplex expression of gRNAs without 5΄-end nucleotide limitations
In designing a dimeric RNA-guided nuclease platform, we realized that the targeting range of such a system would be very low if we used existing gRNA expression methods. Two sequence requirements typically restrict the targeting range of a dCas9 monomer: the requirement for a PAM sequence of 5ʹ-NGG that is specified by dCas9 (ref. 14) and a requirement for a G nucleotide at the 5ʹ end of the gRNA imposed by the use of 
GTCGCCCTCGAACTTCACCTCGG
Csy4
Standard Control gRNAs described above that recognize sites with an edge-to-edge distance of 112 bp (Fig. 1d) . Co-expression of these two gRNAs (each flanked by Csy4 recognition sites) together with Csy4 and wild-type Cas9 nuclease in human cells led to the introduction of indel mutations at both EGFP target sites as well as deletion of the sequence between these sites (Fig. 1d) . These results suggest that both gRNAs can be processed from the single parental RNA transcript and are capable of directing Cas9 nuclease activities in human cells. Additionally, the identification of alleles bearing mutations at both sites or deletion of the sequence in between the two sites demonstrates that both gRNAs are being expressed within the same individual cells.
Construction and optimization of dimeric RNA-guided nucleases
We constructed two different hybrid proteins: one in which the FokI nuclease domain is fused to the C terminus of dCas9 (dCas9-FokI) and the other in which it is fused to its N terminus (FokI-dCas9) (Fig. 2a) . The dCas9-FokI protein is analogous in architecture to ZFNs and indels in human cells (note that the single gRNAs expressed in the Csy4-based system in this experiment are flanked by Csy4 cleavage sites). We performed this comparison with three gRNAs targeted to sites in the EGFP reporter gene (Fig. 1c) using a well-established human cellbased EGFP disruption assay 7,13,17 (Online Methods), which can rapidly and easily quantify the induction of Cas9-mediated indels. Our results demonstrate that single gRNAs expressed in our Csy4-based system have Cas9-mediated activities in the EGFP disruption assay that are ~90% of that observed with matched gRNAs made from a standard U6 promoter vector (Fig. 1c) . These results also suggest that the presence of the Csy4 recognition site at the 3' end of the gRNA and an associated Csy4 molecule after RNase processing from the larger transcript do not appear to substantially impair the ability of these gRNAs to direct Cas9-mediated cleavage in human cells. We next sought to determine whether our Csy4-based system could be successfully used to express more than one gRNA from a single transcript. In this experiment, we used two of the three EGFP-targeted of the 12 RFNs we tested introduced indels with high efficiencies (range of 3-40%) at their intended target sites in human U2OS.EGFP cells as judged by T7EI assay ( Table 1) . Similar results were obtained with these same 12 RFN pairs in HEK293 cells ( Table 1) . Sanger sequencing of successfully targeted alleles from U2OS.EGFP cells revealed the introduction of a range of indels (primarily deletions with only a small number of insertions) at the expected cleavage site (Supplementary Fig. 2 ). Direct comparison experiments performed at three of the endogenous gene sites show that the indel frequencies induced by RFNs were only somewhat lower than those observed with wild-type Cas9 nuclease and single gRNAs from those pairs (Supplementary Fig. 3 ). Taken together, our experiments performed in two different human cell lines demonstrate the robustness of RFNs for modifying endogenous human genes.
RFNs possess specificities for extended cleavage sites
To test whether RFNs possess the enhanced recognition specificities expected with dimerization, we examined whether these nucleases strictly depend upon the presence of both gRNAs in a pair. For this we used two pairs of gRNAs that we had shown could efficiently direct FokI-dCas9-induced indels to their target sites in the EGFP reporter gene (EGFP sites 47 and 81) in human U2OS.EGFP cells (Fig. 2c) . Replacement of one or the other gRNA in each of these two pairs with another targeted to an unrelated site in the human vascular endothelial growth factor A (VEGFA) gene resulted in reduction of EGFP disruption activity to a level observed with a negative control (Fig. 3a) and reduction of targeted mutations to undetectable levels as judged by T7EI assays (Fig. 3b) . We performed a similar experiment using gRNA pairs we had shown could efficiently introduce FokI-dCas9-mediated indels in the human APC, MLH1 and VEGFA genes ( Table 1 ) and again observed loss of detectable RFN-induced indels by T7EI assay when only one of the two gRNAs in a pair was present (Fig. 3c) . These results demonstrate that efficient induction of genome editing by an RFN requires two appropriately targeted gRNAs. Given the dependence of RFNs on the expression of two gRNAs, we hypothesized that their mutagenic effects on known off-target sites of single gRNAs in the pair should be negligible. However, performing these direct comparisons requires knowledge of the Cas9-induced offtarget sites of single gRNAs in the pair. We had previously identified five off-target sites for one of the gRNAs we used to target the dimeric RFN site in the human VEGFA gene 7, 13 . Using deep sequencing, we found that the frequency of indel mutations induced by the dimeric RFNs was indistinguishable from background at all five off-target sites TALENs (Fig. 2a) . For both fusions, we used a five-amino-acid linker with the sequence GGGGS to connect the two domains, and the dCas9 domain was codon optimized for expression in zebrafish and human cells. We used the EGFP disruption assay to ascertain whether either or both of these fusions could mediate site-specific cleavage of DNA in human cells. Because we did not know the specific half-site orientations or spacings required for efficient cleavage, we designed 60 pairs of gRNAs targeted to various sites in EGFP. The two half-sites targeted by each of these gRNA pairs were oriented such that both of their PAM sequences are either directly adjacent to the spacer sequence (the "PAM-in" orientation) or positioned at the outer boundaries of the full-length target site (the "PAM-out" orientation) (Fig. 2b) . The spacer sequence was also varied in length from 0 to 31 bp for both the PAM-in and PAM-out orientations (Fig. 2b and Supplementary Table 1) .
The dCas9-FokI protein did not show detectable EGFP disruption activity above the background level of the assay when co-expressed with any of the 60 gRNA pairs in human U2OS.EGFP cells ( Supplementary  Fig. 1 ). However, screening of the FokI-dCas9 protein with the same 60 gRNA pairs did reveal detectable EGFP disruption activity on target sites composed of half-sites in the PAM-out orientation and with spacer lengths of 13-17 bp, with some lower level activity also visible at the 26-bp spacer length (Fig. 2b) . Further testing of FokI-dCas9 on an additional 25 target DNA sites with spacer lengths ranging from 10 to 20 bp and with half-sites in the PAM-out orientation demonstrated efficient cleavage on targets with spacer lengths of 13-18 bp (Fig. 2c,d and Supplementary Table 2) . In these experiments, we were only able to test one site each for spacer lengths of 17 or 18 bp and not all sites with a 13-bp spacer length showed activity. Analysis of a subset of these successfully targeted sites using T7 endonuclease I (T7EI) assay (Online Methods) and Sanger sequencing (Online Methods) confirmed the presence of indels at the intended location (data not shown). We conclude that FokI-dCas9 can be directed by two appropriately positioned gRNAs to efficiently cleave a full-length target site of interest. For simplicity, we refer to the complex of two FokI-dCas9 fusions and two gRNAs as RFNs.
To extend our initial findings with the EGFP reporter gene and to ascertain whether RFNs could be used to perform routine genome editing of endogenous human genes, we designed gRNA pairs for 12 different target sites in nine different human genes ( Table 1) . For these experiments, we used a FokI-dCas9 fusion that we had further optimized for activity by adding nuclear localization signal (NLS) sequences to its N-and C-terminal ends and by codon-optimizing the FokI domain for expression in human cells (data not shown and Online Methods). Eleven Mutation frequencies were measured by t7eI assay with means of triplicate measurements shown (n = 3). Table 4 ). We chose these six particular sites because we had previously determined that monomeric Cas9 nickases directed by one or the other gRNA in these pairs could induce indel mutations at these targets (data not shown). Using deep sequencing, we assessed the genome editing activities of FokI-dCas9 or Cas9 nickase in the presence of both or only one or the other gRNA. We found that FokI-dCas9 and Cas9 nickase induced indels at all six target sites with high efficiencies in the presence of two gRNAs (Supplementary Table 4 ). As expected, monomeric Cas9 nickases directed by the 12 single gRNAs induced indels with frequencies ranging from 0.0048% to 3.04% (mean of 1.02%) (Fig. 4a and Supplementary Table 4) . By contrast, FokI-dCas9 directed by the same 12 single gRNAs induced indels at lower frequencies ranging from 0.0045% to 0.473% (mean of 0.15%) (Fig. 4a and Supplementary Table 4 ). Comparing these data directly, FokI-dCas9 induced indels with lower frequencies than Cas9 nickase for 10 of the 12 single gRNAs ( Fig. 4a and Supplementary Table 4 ). In addition, FokI-dCas9 showed greater fold reductions in indel frequencies than Cas9 nickase at 11 of the 12 half-sites when comparing single gRNA rates to the paired gRNA rates (Fig. 4b) .
Our deep-sequencing experiments also uncovered a previously undescribed side effect of certain monomeric Cas9 nickases: the introduction of point mutations at particular positions within their target sites. Cas9 nickase co-expressed with a single gRNA for the 'right' half-site of the VEGFA target induced base substitutions at position 15 of the recognition site at a frequency of 10.5% (Fig. 5a) . Similar results were observed with Cas9 nickase and single gRNAs directed to the 'right' half-site of the ( Fig. 3d and Supplementary Table 3 ; these are the same cells we used for the T7EI assay shown in Fig. 3c ). These results demonstrate that the use of RFNs can essentially eliminate Cas9-induced off-target effects of a single gRNA and are consistent with our observations that a single gRNA co-expressed with FokI-dCas9 does not efficiently induce indels. At present, it is not possible to perform these direct comparisons for additional sites -such experiments will have to await the identification of off-target sites for more single gRNA sites that can also target the halfsite of a dimeric RFN. Nonetheless, we conclude that dimeric RFNs have enhanced specificities relative to standard monomeric Cas9 nucleases.
Monomeric Cas9 nickases mutagenize more efficiently than FokI-dCas9 guided by a single gRNA As noted above, an important limitation of the paired Cas9 nickase approach is that single monomeric nickases can introduce indel mutations with high frequencies at certain target sites 4, 10, 11, 13 . This lack of dimerization-dependence in the paired Cas9 nickase system is a potential source of off-target effects, with each of the two monomeric nickases having the ability to create unwanted indel mutations elsewhere in the genome. We hypothesized that because FokI nuclease activity is dependent on dimerization, our FokI-dCas9 fusions should generally show less undesirable indel activity in the presence of only one gRNA when compared directly with monomeric Cas9 nickases.
To test this hypothesis, we compared the activities of FokI-dCas9 and Cas9 nickase in the presence of a single gRNA at six dimeric human gene target sites (a total of 12 gRNAs for 12 half-sites; Supplementary and VEGFA. For each target, we co-expressed FokI-dCas9 with a pair of cognate gRNAs, only one gRNA for the 'left' half-site, or only one gRNA for the 'right' half-site. Rates of mutagenesis were measured by t7eI assay. APC, adenomatous polyposis coli; MLH1, mutl homolog 1. error bars represent s.e.m., n = 3. (d) Mutagenesis frequencies of RFNs targeted to VEGFA site 1 at the on-target site and at five previously known off-target (Ot) sites for one of the gRNAs used to target VEGFA site 1. Frequencies of mutation were determined by deep sequencing, and these data are also shown in Supplementary Table 3 . each value reported was determined from a single deep-sequencing library prepared from genomic DNA pooled from three independent transfection experiments. the value shown for the on-target VEGFA site 1 (marked with an asterisk) is the same as the one shown in Figure 4a in which the FokI domain is fused to the C terminus of engineered zinc finger or transcription activator like effector repeat arrays. RFNs also require that the half-sites bound by each gRNA/FokI-dCas9 complex have a particular relative orientation (PAMs-out) with a restricted intervening spacer length of 14-17 bp (although activity may be possible at additional spacings but with less consistent success). In retrospect, it is now possible to rationalize why the FokI-dCas9 architecture worked in light of recent structural information about the dCas9/gRNA/DNA complex 18, 19 , though we did not have these insights at the time we designed and optimized the activity of our RFNs. A key component of our RFN platform is the Csy4-based methodology for expressing pairs of gRNAs processed from a single transcript. This method enables multiple gRNAs bearing any nucleotide at their 5ʹ ends to be expressed, in contrast to standard vectors that utilize a U6 promoter and therefore require a 5' G for efficient expression of a single gRNA. The relief of this 5'-end sequence restriction is critically important because it enables a more reasonable RFN targeting range of one site in every 37 to 64 bps of random DNA sequence rather than one site in every 1,024 bps (Supplementary Discussion). Beyond improving RFN targeting range, our multiplex gRNA system might also be used to enable the expression of gRNAs from RNA polymerase II promoters, thereby providing potential opportunities for inducible and/or cell-typespecific control. Our Csy4-based system should prove generally useful for any application requiring the expression of two or more gRNAs (e.g., the targeting of multiple dCas9-activator proteins to achieve synergistic upregulation of gene expression [20] [21] [22] ). Other systems, such as a recently described ribozyme-based system 23 , might also provide alternative methods for accomplishing similar goals.
The dimeric nature of RFNs provides important specificity advantages relative to standard monomeric Cas9 nucleases. Our data demonstrate that FokI-dCas9 directed by a single gRNA induces very little or no mutagenesis at RFN half-sites. Given that the FokI nuclease domain must dimerize to cleave DNA, we presume that any indels we observe with a single gRNA are likely due to recruitment of two FokI-dCas9 molecules to the DNA. Regardless of mechanism, given that we observed only a very low level or no mutagenesis when testing FokI-dCas9 with single gRNAs at 12 on-target half-sites, it is very unlikely that any mutagenesis will be induced at partially mismatched, off-target half-sites. Consistent with this, we confirmed that an RFN targeted to VEGFA did not induce detectable mutations at known off-target sites of one of the gRNAs as judged by deep sequencing.
We also expect that RFNs will not induce appreciable off-target mutations as dimers in human cells. RFNs, directed by a pair of gRNAs to cleave a full-length sequence composed of two half-sites, would be expected to specify up to 44 bp of DNA in their target sites. A sequence of this length will, by chance, almost always be unique (except in certain circumstances where the target might lie in duplicated genome sequence). In addition, the most closely matched sites in the genome to this longer dimeric site should, in most cases, possess a large number of mismatches, which in turn would be expected to minimize or abolish cleavage activity by an RFN dimer. For example, we computationally identified all sites in the human genome that bear 0 to 16 mismatches (and that allow for spacers 14-17 bp in length) for the 15 full-length sequences we successfully targeted with RFNs in this study (Online Methods). This analysis found that all 15 target sequences were unique and that the most closely matched sites harbored 7 to 12 mismatches (Supplementary Table 5 ). As expected, deep-sequencing experiments did not detect indel mutations above background at any of the eight most closely mismatched sites for three of these target sequences (Supplementary Table 6 ). It will be interesting in future studies to examine more potential genomic off-target sites for additional dimeric FANCF target site 1 (mutation frequency of 16.3% at position 15) (Fig. 5b) and to the 'right' half-site of the RUNX1 target site (mutation frequency of 2% at position 16) (Fig. 5c) . We also detected these mutations at the VEGFA and FANCF site 1 target sites using Sanger sequencing, demonstrating that these base substitutions are not artifacts caused by the use of a deep-sequencing method (Supplementary Fig. 4 ). In addition, mutations at these positions are not seen above background levels in control samples in which no Cas9 nickase or gRNA are expressed in the cell (Fig. 5a-c) . These point mutations are observed at much lower frequencies (5-to 100-fold lower) in cells that express FokI-dCas9 protein and the same gRNAs (Fig. 5a-c) , suggesting that these mutations are more efficiently induced by Cas9 nickases. Overall, we conclude that single Cas9 nickases can, at certain sites, induce mutagenic indel and point mutations with high frequencies, an effect that is not observed as strongly with FokI-dCas9 nucleases directed by matched single gRNAs.
DISCUSSION
In this report, we have described customizable dimeric RNA-guided nucleases for performing robust and highly specific genome editing in human cells. A key advantage of our RFNs is that, in contrast to standard monomeric Cas9 nucleases, they function as dimers and require two gRNAs for enzymatic activity. The engineering of an active RFN required fusion of the FokI nuclease domain to the N terminus of the dCas9 protein, an architecture different from that of ZFNs and TALENs genesis. However, our observation that FokI-dCas9 directed by a single gRNA appears to induce these mutations at much lower frequencies suggests that strand separation alone may not be sufficient to induce base substitutions efficiently and that perhaps the nick induced by Cas9 nickases enhances the mutagenic effect. Notably, for all three cases, the base position mutagenized within the binding site is a cytosine preceded by a thymine on the noncomplementary strand, perhaps suggesting the involvement of APOBEC proteins that preferentially recognize and deaminate cytosines at TC sequences and that can be overexpressed in transformed cancer cell lines 24, 25 . Further studies will be needed to clarify the mechanism by which these substitutions are induced by Cas9 nickases and to determine whether this effect might also occur in noncancer cell lines. In the course of developing RFNs, we have created software tools that should be useful for applying the technology. To aid in identification of potential full-length RFN target sites, we have added a new module to our existing ZiFiT Targeter software 26 (http://zifit.partners.org/) that can search user-defined DNA sequences. The output from ZiFiT Targeter also provides the sequences of oligonucleotides to be synthesized and cloned for expression of specific gRNAs in our Csy4-based system. In addition, we developed a software program to identify potential offtarget sites of RFN dimers in the human genome based on mismatches to the full-length target site. This program can be used to determine whether a given dimeric full-length RFN target site is unique in the human genome as well as to provide information about the orthogonality of any given site relative to the rest of the genome. We have made this program freely available for download at this website: https://bitbucket. org/vishalthapar/casper-scan.
As the mechanism of genome editing by hybrid proteins harboring FokI nuclease domains has been well studied and extensively characterized, further improvements in specificity can potentially be added to the basic RFN architecture described here by making well-defined alterations to the FokI domain. For example, the residual mutagenic activity observed in the presence of single gRNAs might be further reduced or eliminated by constructing RFNs that harbor obligate heterodimeric RFNs targeted to endogenous genes. Overall, we conclude that dimeric RFNs should possess a high degree of specificity in human cells, but the ultimate characterization of specificity will await the development of unbiased methods that can comprehensively define RFN cleavage specificity across the entire genome.
Because RFNs are a true dimeric system, they possess a number of important advantages over co-localized, paired Cas9 nickases, which do not possess dimerization-dependent enzymatic activities. First, direct comparisons show that single Cas9 nickases generally induce unwanted indel mutations with higher rates than FokI-dCas9 fusion proteins directed by the same individual gRNAs. Second, monomeric Cas9 nickases can in some cases also induce unwanted base pair substitutions into their target sites with high efficiencies, which is, to the best of our knowledge, a previously unknown mutagenic side effect that we uncovered in this study (see additional discussion below). Cas9 nickases induce these unwanted point mutations at substantially higher rates than FokI-dCas9 fusions guided by the same matched single gRNAs. Third, paired Cas9 nickases show greater promiscuity in the orientation and spacing of target half-sites than dimeric RFNs and, therefore, have a greater potential range of sites at which off-target mutations might be induced. Paired nickase half-sites can be oriented in a PAM-in or PAMout configuration and with spacer sequences ranging in length from 0 to 1,000 bp [10] [11] [12] . By contrast, RFNs are much more stringent in their specificities-half-sites must be in a PAM-out orientation with a more limited set of spacer lengths (e.g.,14-17 bps), a requirement presumably enforced by the need to appropriately position two FokI cleavage domains to allow efficient dimerization.
The mechanism of the induction of base-substitution mutations within the recognition sequence of certain sites when using single or paired Cas9 nickases is presently unclear. For all three sites at which we observed these mutations, the base that is most efficiently altered falls within a strand-separated region of the target DNA, which has been reported to be susceptible to P1 nuclease in vitro in a dCas9/gRNA/ target DNA complex 19 . Perhaps DNA distortions induced by binding of Cas9 might trigger the base-excision repair pathway, leading to muta- nickase or a tdtomato control. Mutation frequencies were determined by deep sequencing. each point mutation value reported was determined from a single deep-sequencing library prepared from genomic DNA pooled from three independent transfection experiments. Note that the genomic DNA used for these experiments was isolated from the same cells analyzed for indel mutations in Figure 4 . FANCF, Fanconi anemia, complementation group F; RUNX1, runtrelated transcription factor 1. FokI domains [27] [28] [29] and other orthologous Cas9/gRNA pairings 30 . Additionally, strategies used to improve the specificity of monomeric Cas9 nucleases (e.g., truncated gRNAs recently described by our laboratory 13 ) might also be used to eliminate any potential residual off-target effects induced by RFNs. The improved specificities of RFNs should make them broadly useful for research and therapeutic applications requiring high-precision genome editing.
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